{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:26:33Z","timestamp":1758702393775,"version":"3.37.3"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,24]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Extraintestinal manifestations are common in patients with chronic inflammatory bowel disease (IBD). Peripheral arthritis occurs in \u223c10% of patients with IBD. Treatment of both arthritis and the IBD disease is challenging, and involvement of both the rheumatologist and the gastroenterologist is essential. We present a case with concomitant polyarthritis and ulcerative colitis successfully treated with tofacitinib. A 32-year-old woman with ulcerative colitis currently treated with azathioprine and adalimumab was referred to our rheumatology clinic due to pain and swelling in her knees and finger joints. The patient was diagnosed with IBD-related arthritis. Intra-articular injection with steroid was initially effective, but the arthritis was persistent. Treatment attempts with salazopyrine and golimumab were discontinued due to drug-induced pancreatitis and urticaria, respectively. Subsequently treatment with tofacitinib 10\u2009mg twice daily was effective within weeks, and apart from a mild folliculitis, there were no side effects. With this case report, we would like to draw attention to the fact that treatment with tofacitinib may constitute a good treatment option in refractory cases of IBD-related arthritis.<\/jats:p>","DOI":"10.1093\/mrcr\/rxac021","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T08:10:41Z","timestamp":1646813441000},"page":"171-172","source":"Crossref","is-referenced-by-count":3,"title":["Effect of tofacitinib in a patient with inflammatory bowel disease\u2013related arthritis"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6871-9837","authenticated-orcid":false,"given":"Niels","family":"Lomborg","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Section of Rheumatology, Lillebaelt Hospital , Vejle, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Dam","family":"Jensen","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, Lillebaelt Hospital , Vejle, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"2022062410310779200_R1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"key":"2022062410310779200_R2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41584-020-0454-9","article-title":"Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis","volume":"16","author":"Gracey","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2022062410310779200_R3","first-page":"631","article-title":"Incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis","volume":"11","author":"Karreman","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2022062410310779200_R4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.autrev.2014.04.003","article-title":"Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease","volume":"13","author":"Olivieri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2022062410310779200_R5","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1093\/rheumatology\/keaa107","article-title":"Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab","volume":"59","author":"Dupre","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2022062410310779200_R6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.semarthrit.2008.06.004","article-title":"Emergence of Crohn\u2019s disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action","volume":"39","author":"Haraoui","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"2022062410310779200_R7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40265-020-01460-3","article-title":"Vedolizumab and extraintestinal manifestations in inflammatory bowel disease","volume":"81","author":"Hanzel","year":"2021","journal-title":"Drugs"},{"key":"2022062410310779200_R8","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2022062410310779200_R9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2022062410310779200_R10","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211005708","article-title":"Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis","volume":"14","author":"Rubin","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2022062410310779200_R11","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000226","article-title":"Use of tofacitinib for the treatment of arthritis associated with ulcerative colitis","volume":"6","author":"Wang","year":"2019","journal-title":"ACG Case Rep J"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxac021\/42992319\/rxac021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/2\/171\/44245086\/rxac021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/6\/2\/171\/44245086\/rxac021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T10:31:24Z","timestamp":1656066684000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/6\/2\/171\/6545165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":11,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,9]]},"published-print":{"date-parts":[[2022,6,24]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxac021","relation":{},"ISSN":["2472-5625"],"issn-type":[{"type":"electronic","value":"2472-5625"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,3,9]]}}}